Kronos Bio Inc expected to post a loss of 59 cents a share - Earnings Preview

Kronos Bio

20/02/2023 11:44

* Kronos Bio Inc  KRON.OQ   KRON.O  is expected to show no
change
in quarterly revenue when it reports  results on February 22
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Kronos Bio Inc is
for a
loss of 59 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kronos Bio
Inc is
$10​, above​ its last closing price of $2.03. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.65       -0.65      -0.57     Beat    12.6
 Jun. 30 2022  -0.69       -0.69      -0.59     Beat    14.7
 Mar. 31 2022  -0.65       -0.66      -0.65     Beat    1.2​
 Dec. 31 2021  -1.08       -1.10      -1.13     Missed  -2.9
 ​​Sep.        -0.99       -1.01      -0.61     Beat    39.7
 30 2021                                                
 Jun. 30 2021  -0.59       -0.62      -0.53     Beat    14.8​
 Mar. 31 2021  -0.43       -0.43      -0.48     Missed  -10.7
 Dec. 31 2020  -0.76       -0.79      -0.70     Beat    11.1
 This summary was machine generated February 20 at 11:44 GMT. 
All figures in US dollars  unless otherwise stated